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Review
Objectives: There is no systematic review on economic evaluations of telemedicine in Japan, despite over 1000 trials implemented. 
Our systematic review aims to examine whether Japan’s telemedicine is cost-saving or cost-effective, examine the methodological 
rigorousness of the economic evaluations, and discuss future studies needed to improve telemedicine’s financial sustainability. 
Methods: We searched five databases, including two Japanese databases, to find peer-reviewed articles published between January 1, 
2000 and December 31, 2014 in English and Japanese that performed economic evaluations of Japan’s telemedicine programs. The 
methodological rigorousness of the economic analyses was assessed with a well-established checklist. We calculated the benefit-to-cost 
ratio (BCR) when a reviewed study reported related data but did not report the BCR. All cost values were adjusted to 2014 US dollars. 
Results: Among the 17 articles identified, six studies reported on settings connecting physicians for specialist consultations, and elev-
en studies on settings connecting healthcare providers and patients at home. There are three cost-benefit analyses and three cost-
minimization analyses. The remaining studies measured the benefit of telemedicine only, using medical expenditure saved or users’ 
willingness-to-pay. There was substantial diversity in the methodological rigorousness. Studies on teledermatology and teleradiology 
indicated a favorable level of economic efficiency. Studies on telehomecare gave mixed results. One cost-benefit analysis on tele-
homecare indicated a low economic efficiency, partly due to public subsidy rules, e.g., a too short budget period.
Conclusions: Overall, telemedicine programs in Japan were indicated to have a favorable level of economic efficiency. However, the 
scarcity of the economic literature indicates the need for further rigorous economic evaluation studies. 
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INTRODUCTION
Telemedicine, broadly defined as the use of medical infor-
mation exchanged from one site to another via electronic 
communications to improve a patient’s clinical health status 
[1], has been expected to improve simultaneously the cost of, 
quality of, and access to healthcare. There are over 80 system-
atic reviews on the effectiveness of telemedicine and more 
than 20 of them reporting conclusively that telemedicine is ef-
fective [2] in such areas as mental health [3-5] and manage-
ment of chronic diseases [6-8] including diabetes, heart failure, 
and elderly care [9,10]. 
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However, previous systematic reviews on the economic 
evaluation of telemedicine, based on study populations in the 
US, the UK, and Australia, show there is no conclusive evi-
dence that telemedicine interventions are cost-saving or cost-
effective compared to conventional health care [11-14]. In 
many countries, it has been reported that a large number of 
telemedicine programs have been started on a trial basis but 
discontinued for larger scale implementation due to lack of 
sustainable financial sources [15-19]. This is mainly because 
most insurers do not reimburse new types of healthcare deliv-
ery [20-22]. For this reason, several studies have stated that 
comprehensive cost-effectiveness studies are essential in jus-
tifying insurer coverage and reimbursement for telemedicine 
in the future [23,24].
Japan has faced a growing proportion of elderly people 
amidst a declining overall population. In 2014, the proportion 
of the population aged 65 or older was estimated to be 
25.9%—the highest proportion in the world [25]. Currently, 
two major healthcare issues in Japan are the increasing total 
cost of healthcare and the uneven distribution of healthcare 
resources. The latter issue limits the access of remotely located 
people to sufficient healthcare services. Telemedicine is 
deemed to be a potential solution for these current twofold is-
sues. 
Based on the budget records issued by Japan’s Ministry of 
Finance, we calculated public expenditure for development 
and pilot trials of health information technology, including 
telemedicine, from 2008 to 2014—the result was $1.5 billion. 
Despite such enormous amounts in public subsidies for tele-
medicine, the literature indicated serious concern about the fi-
nancial sustainability of telemedicine [26,27]. 
Among the studies reporting the effectiveness of telemedi-
cine experiments around the country, only a small subset of 
these studies conducted an economic evaluation. The absence 
of a cohesive body of rigorous economic evaluation studies 
may be one of the key obstacles to the widespread adoption, 
proliferation, and funding of telemedicine programs [9,28-30].
This study’s aim was to conduct a systematic review to iden-
tify and analyze the published economic evaluations on tele-
medicine in Japan. This qualitative assessment has three ob-
jectives: (a) to identify whether, and in what areas, telemedi-
cine was evaluated to achieve a favorable level of economic 
efficiency, that is, whether it was cost-saving or cost-effective 
in Japan; (b) to assess the methodological rigorousness of the 
economic evaluations; and (c) to discuss future studies neces-
sary to improve the general financial sustainability of tele-
medicine.
METHODS
This article focuses on telemedicine in broader health areas 
to make the results more comprehensive. Specifically, this 
study gathered economic evaluations of telemedicine con-
necting “non-specialized physicians and specialized physi-
cians,” “physicians and patients,” and “public health nurses and 
patients.” 
Search Strategy
We searched the following databases: PubMed/MEDLINE, 
Web of Science, IEEE Xplore, Ichushi-Web database (the largest 
Japanese health database), and CiNii Articles (the largest Japa-
nese database in all academic fields). All peer-reviewed arti-
cles published between January 1, 2000 and December 31, 
2014 in English and Japanese were selected if they included 
any type of economic evaluation in monetary terms. 
The inclusion criteria regarding economic evaluation were 
full economic evaluation [31] (i.e., cost-minimization analysis 
[CMA], cost-effectiveness analysis [CEA], cost-utility analysis 
[CUA], cost-benefit analysis [CBA]), cost-only analysis, or bene-
fit-only analysis. The exclusion criteria were articles that de-
scribed only effectiveness or benefit in non-monetary terms 
and articles available only in abstract form. Table 1 shows the 
different and exact combinations of keywords, relating to eco-
nomic evaluation and telemedicine, used in this research. We 
used comparable Japanese words for Japanese databases. 
Review Process
The selection process for the articles involved reading the ti-
tles and abstracts of the results obtained by one of the au-
thors. After duplicate articles were deleted, all abstracts were 
read for relevance based on the inclusion and exclusion crite-
ria. The relevant full-text articles were then obtained and thor-
oughly read by two authors. A classification of the telemedi-
cine types, economic-analysis types, study designs, study pop-
ulations, time frames, and the selection for the final appraisal 
were obtained by reading both the abstracts and the entire ar-
ticles. In case of any disagreement, the two authors discussed 
the article and one designated author made the final decision. 
In order to compare a variety of studies conducted in differ-
ent time periods, we made a purchasing power parity adjust-
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ment and converted all costs to 2014 US dollars using the con-
sumer price index [25].
Economic Evaluation Quality Assessment
We critically assessed the methodological rigorousness of 
the economic evaluation for each article based on the latest 
version of the checklist developed by Drummond et al. [31]. 
This checklist was chosen partly because it was one of the 
most widely used assessment tools in this area, e.g., this 
checklist’s older version was known and widely used as “the 
BMJ Check-List” [32,33]. The most recent version of this check-
list, published in 2015 [31], contains 87 items under ten head-
ings (detailed in Table 2). Assessors are asked to check either 
“yes,” “no,” or “not applicable” (N/A) for each of ten subheadings 
according to the relative importance subjectively conferred to 
each item under each subheading. There is no explicit weight-
ing for each item to calculate a single aggregated score. This 
checklist concentrates on full economic evaluations, but could 
also be used for partial economic evaluations, reports, and 
commentaries on economic evaluations. If items were not ap-
plicable to a specific study, a “N/A” response could be used. 
Miki Akiyama and Byung-Kwang Yoo graded three studies 
using the criteria in order to reach consensus on the interpre-
tation of the criteria, and Miki Akiyama graded the remaining 
papers.
Supplemental Estimation Based on Published 
Data
When a reviewed study reported cost and benefit but did 
not report the benefit-to-cost ratio (BCR) [34-36], we made a 
supplemental estimation of BCR by dividing the reported fi-
nancial benefit by the reported cost [31]. The financial benefit 
was estimated as the reduced medical care expenditure with-
out assigning any monetary value for an improvement in 
health outcome. 
RESULTS
Summary of Identified Literature 
Figure 1 shows a flowchart with the steps followed in this 
review. The initial screening of the electronic databases re-
trieved 138 titles and abstracts; after the removal of duplicates 
Table 1. Search strategy
Database1 Keywords for search
PubMed/MEDLINE ("costs and cost analysis"[MeSH terms] OR "cost benefit analysis"[MeSH terms] OR "cost effectiveness" OR "cost utility") AND  
   ("telemedicine"[MeSH terms] OR telecare OR telehealth OR e-health) AND Japan
Web of Science TS= ("cost$analysis" OR "cost*benefit" OR "cost*effectiveness" OR "cost*utility" OR "economic evaluation") AND TS= (telemedicine 
   OR tele*care OR tele*health OR e*health) AND TS= (Japan*)
IEEE Xplore ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telec 
   are OR telehealth OR e-health) AND Japan
Ichushi-Web2 (in Japanese) Within "Original Article" category, used ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR  
   "economic evaluation") AND (telemedicine OR telecare OR telehealth OR e-health) 
CiNii Articles2 (in Japanese)  ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND  
   (telemedicine OR telecare OR telehealth OR e-health) 
1The index period was 2000-2014 except for IEEE Xplore, which only allowed a search of journals published after 2002.
2For Japanese databases, relevant keywords were used, and the word “Japan” was not used. 
Figure 1. Flowchart of the steps followed in this review.
Search hits (n=138)
-  PubMed (n=16)
-  Web of Science (n=4)
- IEEE Xplore (n=90)
- Ichushi-Web (n=19)
- CiNii Articles (n=9)
Excluded (n=74)
- Irrelevant title (62)
- Duplicate paper (12)
Excluded (n=35)
- Unpromising abstract (n=28)
- Full text not available (n=7)
Excluded (n=12)
- Did not meet the inclusion criteria
- Duplicate reports
Abstract screened
(n=64)
Full papers for appraisal
(n=29)
Final appraisal
(n=17)
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Table 2. A checklist for assessing the quality of economic evaluations1 [31]
Contain items 
1. Was a well-defined question posed in answerable form?
1.1. Did the study examine both costs and effects of the service(s) or programme(s) over an appropriate time horizon?
1.2. Did the study involve a comparison of alternatives?
1.3. Was a viewpoint for the analysis stated and was the study placed in any particular decision-making context?
1.4. Where the patient population and any relevant subgroups adequately defined?
2. Was a comprehensive description of the competing alternatives given (i.e. can you tell who did what to whom, where, and how often)?
2.1. Were there any important alternatives omitted?
2.2. Was (should) a do-nothing alternative (be) considered?
2.3. Were relevant alternatives identified for the patient subgroups?
3. Was the effectiveness of the programme or services established?
3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?
3.2. Was effectiveness established through an overview of clinical studies? If so, were the search strategy and rules for inclusion or exclusion outlined?
3.3. Were observational data or assumptions used to establish effectiveness? If so, were any potential biases recognized?
4. Were all the important and relevant costs and consequences for each alternative identified?
4.1. Was the range wide enough for the research question at hand?
4.2.  Did it cover all relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those of patients and third-party payers. Other viewpoints may 
also be relevant depending upon the particular analysis.)
4.3. Were the capital costs, as well as operating costs, included?
5.  Were costs and consequences measured accurately in appropriate physical units (e.g. hours of nursing time, number of physician visits, lost work-days, 
gained life years)?
5.1. Were the sources of resource utilization described and justified?
5.2. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?
5.3. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?
6. Were the cost and consequences valued credibly?
6.1.  Were the sources of all values clearly identified? (Possible sources include market values, patient or client preferences and views, policy-makers’ views and health 
professionals’ judgements)
6.2. Were market values employed for changes involving resources gained or depleted?
6.3.  Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjust-
ments made to approximate market values?
6.4.  Was the valuation of consequences appropriate for the question posed (i.e. has the appropriate type or types of analysis – cost-effectiveness, cost-benefit, cost-utility – 
been selected)?
7. Were costs and consequences adjusted for differential timing?
7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?
7.2. Was there any justification given for the discount rate used?
8. Was an incremental analysis of costs and consequences of alternatives performed?
8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?
9. Was allowance made for uncertainty in the estimates of costs and consequences?
9.1. If patient-level data on costs or consequences were available, were appropriate statistical analyses performed?
9.2.  If a sensitivity analysis was employed, was justification provided for the form(s) of sensitivity analysis employed and the ranges or distributions of values (for key study 
parameters)?
9.3. Were the conclusions of the study sensitive to the uncertainty in the results, as quantified by the statistical and/or sensitivity analysis? 
9.4. Was heterogeneity in the patient population recognized, for example by presenting study results for relevant subgroups?
10. Did the presentation and discussion of study results include all issues of concern to users?
10.1.  Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)? If so, was the index interpreted intel-
ligently or in a mechanistic fashion?
10.2.  Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodol-
ogy?
10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?
10.4.  Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant 
ethical issues)?
10.5.  Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether 
any freed resources could be redeployed to other worthwhile programmes?
10.6. Were the implications of uncertainty for decision-making, including the need for future research, explored?
1Assessors are asked to check either “yes,” “no,” or “not applicable” for each of the 10 subheadings according to the relative importance subjectively conferred 
to each item under each subheading.
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and irrelevant titles, 64 abstracts remained for screening and 
29 potentially eligible full-text articles were obtained. We ex-
cluded 12 articles after reading the full text, which were 
judged to meet the exclusion criteria. Two were general re-
views of the situation in Asia, one was a review on the meth-
odology of economic evaluation, four were benefit analyses 
using the same survey data, and five papers were not peer re-
viewed. Eventually, 17 peer-reviewed articles containing any 
form of economic appraisal in monetary terms remained. 
Table 3 summarizes the characteristics and key findings of 
the selected studies. Among these studies, 12 were published 
in English [34-45] and five in Japanese [27,46-49]. The service 
settings of telemedicine were categorized into two major 
types: those connecting physicians for specialist consultations 
(the MD–MD setting) [34,35,37-39,49] and those connecting 
healthcare providers and patients [27,36,40-48], which were 
further sub-categorized into settings connecting physicians 
and patients at home (the MD–Patient setting), and those 
connecting public health nurses and patients at home (the 
PhNrs–Patient setting).
Clinical disciplines within MD–MD settings included derma-
tological consultation [35], pediatric medical consultation [49], 
emergency radiotherapy for malignant spinal cord compres-
sion [34], real-time computed tomography (CT) scan indica-
tion [37], teleradiology, and telepathology [38,39]. 
All of the 11 settings connecting healthcare providers and 
patients—that is, the MD–Patient setting and PhNrs–Patient 
setting—dealt with home-based systems with two types of 
functions. One function type is a stand-alone real-time video 
conference system for palliative care for cancer patients with-
out continuous monitoring of vital signs [36]. The other type, 
evaluated by 10 articles [27,40-48], monitors vital signs with 
equipment such as an automated sphygmomanometer and a 
simple electrocardiograph for home. Healthcare providers 
contact a patient when an algorithm for monitored data de-
tects an abnormal vital sign. This type of system targeted life-
style-related diseases such as high blood pressure, diabetes, 
stroke, and heart failure among fragile elderly patients. 
Regarding the types of economic evaluation, they were clas-
sified into four types; three were CBA [34,40,48], which pro-
vide the most useful policy implication, that is, benefit mea-
sured by monetary value compared to input cost of telemedi-
cine. Three studies were categorized as CMA [35-37], which es-
timate the cost reduction by telemedicine compared to a con-
trol group—both telemedicine and control groups achieved 
the same level of health outcome. Four studies [27,43-45] 
measured medical expenditure saved due to telemedicine, 
without calculating the input telemedicine cost or showing 
equal health outcomes. The remaining seven studies [38,39, 
41,42,46,47,49] measured willingness-to-pay (WTP) for using 
telemedicine. There were no CEA or CUA studies. 
MD–MD Specialist Consultation
Out of six studies of MD–MD settings, one clinical efficacy 
study presented detailed estimates of both the costs and ben-
efits of telemedicine in emergency radiotherapy for malignant 
spinal cord compression (MSCC), connecting between a uni-
versity hospital and 10 rural hospitals [34]. Since this study did 
not report the BCR, we calculated the ratios to range from 4.67 
to 13.40. 
There were two CMA studies regarding MD–MD specialist 
live consultations. One CMA study on dermatology consulta-
tion [35] reported cost-saving of $330 per person per week. 
This study’s two-way sensitivity analysis indicated that the 
cost-saving results were sensitive to the two key parameters of 
travel time and consultation time. Assuming that travel time 
was 60 minutes and consultation time was five minutes (based 
on expert opinions from Japanese dermatologists), we calcu-
lated the BCR to be 1.53. 
Another CMA study [37] examined teleradiology diagnosis 
accuracy in an MD–MD setting. This study estimated that tele-
consultation contributed to cost-saving of $144 per reading 
by avoiding unnecessary enhanced CT scans. 
One survey [49] estimated the benefits of specialist telecon-
sultation in pediatric emergency care for primary care physi-
cians in rural, underserved areas. These benefits were mea-
sured by inquiring about WTP among parents of children in 
two rural towns, that is, $31.40 to $33.60 per emergency de-
partment visit.
There were two studies conducted by one study group to 
estimate medical providers’ WTP for teleradiology and telepa-
thology [38,39]. These two studies applied different statistical 
methods for the same set of survey data obtained from 
healthcare providers across Japan, who used either teleradiol-
ogy or telepathology in an MD–MD setting. Their WTP esti-
mates were $489 to $510 for teleradiology and $1063 to 
$1111 for telepathology per person per year.
Healthcare providers–patient homecare
One CMA study [36] on home-palliative care in an MD–Pa-
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two criteria of “uncertainty estimates” and “study results in-
cluding all issues of concern.” 
Publication bias
Figure 2 was created to detect a potential publication bias 
among the reviewed papers. A bold vertical line in this figure 
represents a threshold BCR value of one (also called a break-
even point). A plot located rightward of this threshold vertical 
line indicates a favorable economic efficiency level for a tele-
health program evaluated in the published study. Since the 
plots were skewed to the right of the threshold vertical line 
(i.e., BCR greater than one), Figure 2 implies a moderate bias 
toward publishing more studies with a higher BCR estimate 
for a tele-health intervention. It should be noted that our in-
terpretation regarding such potential publication bias has lim-
ited validity due to the small number of publications with BCR 
estimates.   
DISCUSSION
To our knowledge, this is the first systematic review to sum-
marize the economic efficiency of Japanese telemedicine ser-
Figure 2. Funnel plot for detecting publication bias. A tele-
health intervention is concluded to be cost-saving (i.e., eco-
nomically efficient) when BCR (X-axis in the figure) exceeds 
one (represented by a bold vertical line in the figure). BCR 
takes on any non-negative value. A higher BCR value indi-
cates a more economically efficient health intervention. For 
instance, the interpretation of BCR being two is that a $1 in-
vestment in a telehealth intervention will generate a $2 ben-
efit. Due to the limited number of studies reporting BCR es-
timates, Figure 2 includes four plots of BCR estimates in four 
study sites in one publication [40]. When a reviewed paper 
did not report a single representive BCR estimate (e.g., mean), 
we calculated an average value of multiple BCR estimates.
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tient setting reported that telemedicine could reduce the fre-
quency of physician visits from twice to once a week. The cost-
saving of home palliative care with telemedicine were esti-
mated to be $5000 per person per year compared to conven-
tional home care. A sensitivity analysis of this study showed 
their results to be sensitive to two parameters, the number of 
user patients and duration of service provided. Based on the 
reported benefit, we calculated the BCR to be 1.93. 
One study group published two CBA studies on the same 
type of tele-homecare service operated in different regions 
with different financial schemes: (a) one region where a 
monthly fee was charged and (b) three other regions where 
no fee was charged because of public subsidies. Under the for-
mer scheme, the BCR was calculated to increase monotonical-
ly over time, that is, 1.07 (6-year operation) and 1.28 (11-year 
operation), using WTP estimates among patients in this region 
[48]. Under the latter scheme, the BCR estimates in the three 
regions ranged from 0.54 to 0.61 [40], indicating that tele-
homecare was not cost-saving. 
There were four studies reporting medical expenditure 
saved by telehomecare connecting public health nurses and 
the elderly with chronic diseases in one region [27,43-45]. 
Based on the claims data, these studies showed that treatment 
periods were shortened by telemedicine. Their estimates of re-
duced medical expenditure ranged from $148 to $629 per case 
per year for lifestyle diseases [27,43-45]. However, the input 
costs of telehomecare were not shown in these four studies. 
A single research team produced three survey studies and 
measured patients’ WTP for a telehomecare system that com-
bines vital-signs monitoring and doctor consultation. The WTP 
estimates were $288, $480, and $520 per case per year, de-
pending on three analytical methods [41,46,47]. There was 
only one study conducted in an urban area to estimate users’ 
WTP for home tele-health monitoring. This study, published in 
2012, showed WTP as low as $109 per patient per year [42]. 
Economic Evaluation Quality Assessment
Table 4 summarizes our quality assessment of reviewed 
studies in terms of the ten criteria of the well-established 
checklist from Drummond et al. [31]. There were only four 
studies [35,36,40,48] that met more than eight criteria, and 
eleven studies met only three or fewer criteria. Studies of CBA 
and CMA tended to meet more criteria than studies that mea-
sured only the benefits of telemedicine. Only two studies 
[35,36] conducted a sensitivity analysis, and hence met the 
Funnel plot for detecting publication bias
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vices and to examine the methodological rigorousness of the 
economic evaluation studies conducted in Japan. Despite the 
small number and the diverse quality of economic evaluations 
of telemedicine, most of these evaluations indicated a favor-
able level of economic efficiency, that is, net cost-saving, re-
duced medical expenditure, and/or positive WTP. 
Among studies on MD–MD live consultations in hospital 
settings, the most economically efficient telemedicine was 
emergency radiotherapy consultation about malignant spinal 
cord compression [34]. This study’s results were consistent 
with another effectiveness study of spinal cord compression in 
Canada [50], in terms of decreasing patient transfer and short-
ening treatment decision time. However, the robustness of the 
reported BCR magnitude (>4.67) is uncertain due to the ab-
sence of sensitivity analyses. 
Another cost-saving form of telemedicine in an MD–MD 
hospital setting was teledermatology consultation ($17 160 
per case per year) [35]. This study addressed parameter uncer-
tainty and indicated that whether teledermatology is cost-sav-
ing or not depends on the travel time and consultation time of 
physicians [35]. These results do not contradict the literature 
reporting mixed results; that is, teledermatology cost is either 
lower [51] or higher [52-55] than conventional care costs. 
For an MD–Patient home setting, BCR of telemedicine-com-
bination home palliative care was estimated to be 1.93, com-
pared to the status quo [36]. This CMA was methodologically 
rigorous with regard to (a) a clear statement of the purpose 
and perspective of the study, (b) a detailed illustration of the 
cost estimation, and (c) the implementation of a sensitivity 
analysis. This study in Japan is one of the few studies that ex-
plicitly indicated telemedicine to be cost-saving when used to 
supplement in-person home visits by physicians. Similar real-
time, audio-visual communication services for home palliative 
care have been successfully used for some years in the US [56, 
57] and Australia [58], while investigation in Canada [59] and 
pediatric telepalliative care in Australia [60] faced difficulties. 
In the US, the cost-saving of tele-palliative care was reported 
as due to a reduced number of home visits by nurses [56]. 
Regarding telehomecare among the elderly with chronic 
diseases, two CBAs reported cost-saving when implemented 
in one region (BCR, 1.07 to 1.28) [40,48] where patients’ WTP 
was the only outcome measured. These studies did not ac-
count for the potential reduced medical expenditure due to 
telemedicine. It should be noted that an identical system de-
ployed in three other regions with public subsidies showed 
less economic efficiency (BCR ≤0.61) due to lower WTPs (37% 
to 71% of the similar one-region system above) and higher 
system costs (186% to 195% of the one-region system) [40]. 
The reason for the mixed BCR results can be partly attributed 
to the public subsidy rule. The restrictive rules of public subsidy 
are exemplified by the prohibition on carrying over the budget 
to a second year [40], which may have caused over-utilization 
of the first year cost and hence ultimately decreased BCR. 
The methodological rigorousness of the reviewed studies 
tended to deviate from the established guidelines for eco-
nomic evaluations [31,32,61-63]. For instance, only five studies 
[34-36,40,48] clarified the complete cost measurements of in-
stalling and operating telemedicine, which should have been 
compared with reduced medical expenditure due to the im-
plementation of a telemedicine strategy such as a home telec-
are system (reduced by $148 to $629 per case per year) [27,43-
45] and teleradiology ($144 per CT reading) [37]. Therefore, 
other than these five studies, it seemed very difficult to deter-
mine the accurate economic efficiency level of telemedicine 
among the reviewed studies.
Moreover, none of the reviewed studies implemented a CEA 
or a CUA of the telemedicine program under focus. Therefore, 
it is impossible to judge whether a program is reasonably cost-
effective or not when it is not cost-saving. 
Another example of a common limitation among the re-
viewed studies is the absence or very limited application of a 
probabilistic analysis such as a Monte Carlo simulation in order 
to address the uncertainty of multiple key parameters on cost, 
effectiveness, and benefit, simultaneously [31]. 
In addition to the small number of total publications on the 
topic in focus, there are even fewer studies that examined 
comparable types of telemedicine technology and outcomes. 
This limited number of studies prevented us from performing a 
quantitative summary of the literature, such as a meta-analysis.
We believe that the following types of future studies would 
be useful for an international audience as well as a Japanese 
one. To convince policymakers to initiate and continue public 
subsidies for telemedicine, researchers are expected to pro-
duce more methodologically rigorous empirical evidence, pre-
sented in a reader-friendly manner. The strongest evidence is 
to show cost-saving based on a CBA. Due to diverse costs and 
benefits depending on setting, a probabilistic analysis result is 
useful to report; for example, cost-saving is achieved by tele-
medicine in 57% of 5000 iterations in emergency departments 
[64] and 37% of 1000 iterations in intensive care units [65]. 
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Moreover, hospital level administrators as well as policy-mak-
ers would find it easy to understand a concrete and realistic 
scenario; for example, treating 10 acutely ill and injured chil-
dren at a rural emergency department with telemedicine will 
lead to annual cost-saving of $46 620 per emergency depart-
ment [66]. These decision makers would also appreciate spe-
cific benchmarks to achieve cost-saving, such as maximum al-
lowable cost derived from break-even analyses [65].  
Since telemedicine in a probabilistic analysis is less likely to 
achieve cost-saving in 100% of iterations, a CEA needs to be 
implemented to test whether telemedicine is reasonably cost-
effective or not [31]. To make CEA results of telemedicine com-
parable with other types of health care, a future study is ex-
pected to estimate an incremental cost-effectiveness ratio 
(ICER) with a unit of dollar value per additional quality-adjust-
ed life year (QALY) by the US expert panel on cost-effective-
ness in health and medicine [31,61-63]. A certain telemedicine 
care strategy is concluded to be cost-effective if its ICER is low-
er than a commonly used threshold of $100 000 per QALY [66]. 
These estimates concerning CEA are also appreciated by poli-
cymakers and insurers who are interested in maximizing 
health outcomes under a fixed budget.
Other than improving the methodological rigorousness of 
economic evaluations, our review demonstrated the impor-
tance of WTP measured among users and public subsidy rules. 
The measured WTP could be used as a proxy for a future user 
charge, which is particularly important if the WTP exceeds the 
actual out-of-pocket payment for telemedicine. Partly because 
of the difference in the surveyed populations, WTP for a simi-
lar health-monitoring telemedicine care strategy declined by 
75 percentage points from 2003 to 2010 [42,47]. Potential rea-
sons for the decline include the decreased Japanese purchas-
ing power due to long-term macro-economic recession and 
users’ observations of continuously falling prices in other IT 
products and services. Thus, further studies are needed in 
measuring WTP under various and detailed scenarios as well 
as addressing the impact of public subsidy regulation on BCR. 
These studies could help justify increased public financial sup-
port and hence improve the financial sustainability of tele-
medicine programs.
CONCLUSION
In conclusion, compared to the substantial resources de-
ployed for more than 1000 telemedicine trials in Japan, very 
limited resources have been deployed for the economic evalu-
ation of telemedicine trials. Although most reviewed econom-
ic evaluations reported a favorable level of economic efficien-
cy, their methodological rigorousness tended to vary. Further 
economic evaluation studies in this field are needed with 
more advanced methodological rigorousness and expanded 
research scope (e.g., public subsidy regulation impacts). These 
future studies are expected to help convince various decision 
makers such as policymakers, insurers and hospital adminis-
trators to invest further resources in telemedicine. Conse-
quently, the general financial sustainability of telemedicine is 
expected to improve in the long term. 
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